Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCE.
Article in Diabetes, obesity & metabolism, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06894784 (Semaglutide And Empagliflozin Combination Therapy Added To Automated Insulin Delivery In Adults With Type 1 Diabetes), which is not on this map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT06894784 phase3recruitingstarted 2025, after this paper: background citation
Semaglutide And Empagliflozin Combination Therapy Added To Automated Insulin Delivery In Adults With Type 1 Diabetes (SEMPA)
Ran2025Enrolled36Registered outcomes13Posted comparisons0ConditionsDiabetes Type 1ArmsIntervention Period 1: Semaglutide + Empagliflozin, Intervention Period 2: Semaglutide + Empagliflozin Placebo, Intervention Period 3: Semaglutide Placebo + Empagliflozin, Intervention Period 4: Semaglutide Placebo + Empagliflozin Placebo
Fernando G AngJanssen, Inc., Toronto, Ontario, Canada.
Jochen SeufertDivision of Endocrinology and Diabetology, Department of Medicine II, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID 0000-0001-5654-7310
Brendon L NeuenThe George Institute for Global Health, UNSW Sydney, Sydney, New South Wales, Australia.ORCID 0000-0001-9276-8380
Clare ArnottThe George Institute for Global Health, UNSW Sydney, Sydney, New South Wales, Australia.ORCID 0000-0001-9370-9913
Kenneth W MahaffeyStanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
David C WheelerCentre for Nephrology, University College London, London, UK.
Janssen (Belgium) · BECenter for Clinical Research (United States) · USMcGill University Health Centre · CASt Michaels Hospital · GBSunnybrook Hospital · CAThe University of Sydney · AUUniversity College London · GBUniversity of Freiburg · DEUNSW Sydney · AUWashington Sea Grant · US
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
PubMed holds no abstract for this paper.
Indexed as
Cardiovascular DiseasesCardiovascular SystemDiabetes Mellitus, Type 2CanagliflozinHumansKidneyCanagliflozincanagliflozincardiovascular diseasediabetic nephropathytype 2 diabetes
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.